Fisher & Paykel Healthcare stock gets NZD 45.3 million land deal

Published on 10/07/2026 at 00:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fisher & Paykel Healthcare stock was at NZD 46.46 on October 7, 2026, while Health New Zealand agreed to pay NZD 45.3 million for 13 hectares. FY2026 revenue rose 14 percent.

FPH, NZFAPE0001S2, Illustration mit AI erstellt.

Fisher & Paykel Healthcare (ISIN NZFAPE0001S2) was trading at NZD 46.46 on the NZX on October 7, 2026, down 0.09 percent from the previous close. The company’s latest corporate event is a NZD 45.3 million land sale to Health New Zealand, announced on October 5, 2026.

Land sale supports second campus

According to Fisher & Paykel Healthcare, Health New Zealand will acquire 13 hectares of the company’s 105-hectare Karaka Road site in Drury. The land is intended for a future hospital serving South Auckland, while Fisher & Paykel Healthcare will retain the remaining area for its planned second New Zealand campus.

Settlement is scheduled between March and June 2027, subject to sale conditions, and the transaction will appear as an abnormal item in the income statement. The company said its full-year earnings guidance issued on August 21, 2026, does not include the transaction’s impact, making the sale a separate balance-sheet and property development issue rather than a change to operating guidance.

Revenue growth remains the key figure

For fiscal year 2026, revenue rose 14 percent to NZD 2.31 billion and net income increased 24 percent to NZD 468.5 million, according to Simply Wall St. The period ended March 31, 2026, so the comparison gives investors a recent full-year operating baseline while the land sale adds a separate property-related item.

The company designs and manufactures products for acute and chronic respiratory care, surgery and obstructive sleep apnea treatment. Its products are sold in more than 120 countries, and hospital demand remains central to the growth case described in recent analyst commentary.

Consensus stays close to the share price

Investing.com lists an overall consensus of Buy from 11 analysts, comprising 7 Buy, 4 Hold and 1 Sell ratings. The 12-month average target is NZD 45.13, with targets spanning NZD 31 to NZD 52, placing the current NZX quotation above the published average target.

That spread matters because the optimistic end of the range depends on continued hospital expansion and operating leverage, while the lower targets reflect valuation risk. The latest market quotation is NZD 46.46, only NZD 0.54 below the 52-week high of NZD 47.00.

FPH stock remains near its yearly high

FPH stock was last at NZD 46.46 on the NZX on October 7, 2026, at 11:21 a.m. NZDT. Its market capitalization was NZD 27.3 billion, and the session volume was 2,606 shares.